LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.
Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE:ADCT) in Jan 2012 and served as its CEO since inception until May 2022. Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York Stock Exchange (NYSE) listed leader in the field of ADCs with products on the global market. Chris previously co-founded and led two other biotech companies: Spirogen Ltd, an innovator of ADC payload technology, which was acquired by MedImmune, now part of AstraZeneca; and Sciona, Inc. a provider of personalised gene-based health and nutrition analyses. Alongside his role as Chairman of Myricx, he is also Chairman of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Board of Osivax SAS.
Dr Martin succeeds Prof Roberto Solari, co-founder of Myricx who is stepping down from the board but will remain closely involved as a consultant to the company contributing his extensive drug discovery experience and knowledge.
A Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow, Dr Martin holds a bachelor's degree in chemical engineering from ...